TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$2.43 +0.05 (+2.10%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades About Medexus Pharmaceuticals Stock (TSE:MDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDP alerts:Sign Up Key Stats Today's RangeC$2.38▼C$2.4450-Day RangeC$2.33▼C$2.7352-Week RangeC$1.44▼C$3.16Volume9,972 shsAverage Volume40,814 shsMarket CapitalizationC$59.61 millionP/E Ratio48.60Dividend YieldN/APrice TargetC$5.88Consensus RatingStrong Buy Company OverviewMedexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Medexus Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks46th Percentile Overall ScoreMDP MarketRank™: Medexus Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingMedexus Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedexus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Medexus Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Medexus Pharmaceuticals is 48.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Medexus Pharmaceuticals is 48.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.37.Price to Book Value per Share RatioMedexus Pharmaceuticals has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Medexus Pharmaceuticals' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MDP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedexus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMedexus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MDP. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Medexus Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Medexus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$10,916.00 in company stock and sold C$0.00 in company stock.Percentage Held by InsidersOnly 9.14% of the stock of Medexus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.32% of the stock of Medexus Pharmaceuticals is held by institutions.Read more about Medexus Pharmaceuticals' insider trading history. Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDP Stock News HeadlinesFDA extends review period for Medexus' treosulfan to 2025September 16, 2024 | msn.comSome May Be Optimistic About Medexus Pharmaceuticals' (TSE:MDP) EarningsAugust 20, 2024 | finance.yahoo.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextAugust 10, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc (MDP)May 24, 2024 | investing.comWith A Return On Equity Of 20%, Has Medexus Pharmaceuticals Inc.'s (TSE:MDP) Management Done Well?May 8, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc (P731.BE)February 13, 2024 | au.finance.yahoo.comMedexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen NextFebruary 10, 2024 | finance.yahoo.comSee More Headlines MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$2.47 at the beginning of 2024. Since then, MDP shares have decreased by 1.6% and is now trading at C$2.43. View the best growth stocks for 2024 here. How were Medexus Pharmaceuticals' earnings last quarter? Medexus Pharmaceuticals Inc. (TSE:MDP) posted its quarterly earnings results on Wednesday, August, 7th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.07. The firm earned $37.33 million during the quarter, compared to analysts' expectations of $36.95 million. Medexus Pharmaceuticals had a net margin of 1.00% and a trailing twelve-month return on equity of 3.95%. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS). Company Calendar Last Earnings8/07/2024Today11/02/2024Next Earnings (Confirmed)11/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:MDP CUSIPN/A CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Stock Price TargetC$5.88 High Stock Price TargetC$8.25 Low Stock Price TargetC$3.50 Potential Upside/Downside+141.8%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)C$0.05 Trailing P/E Ratio48.60 Forward P/E Ratio14.88 P/E GrowthN/ANet IncomeC$1.09 million Net Margins1.00% Pretax MarginN/A Return on Equity3.95% Return on Assets4.89% Debt Debt-to-Equity Ratio143.72 Current Ratio1.11 Quick RatioN/A Sales & Book Value Annual SalesC$108.78 million Price / Sales0.55 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.33 per share Price / Book1.83Miscellaneous Outstanding Shares24,530,000Free FloatN/AMarket CapC$59.61 million OptionableNot Optionable Beta1.96 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (TSE:MDP) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.